[Pharmacokinetic and clinical studies on XXXX in the perinatal period].

@entity7288 @entity8934 @entity5870 @entity8933 @entity2885 @entity221
Pharmacokinetic and clinical studies were carried out on the use of @entity8933 ( @entity8934 ) in the perinatal period. The results obtained are summarized below. 1. Mean maternal serum concentrations of @entity8934 reached 57.3 micrograms/ml at about 15 minutes after a single intravenous injection of @entity8934 1 g and then gradually decreased to 13.1 micrograms/ml in 1 hour and 55 minutes, 3.59 micrograms/ml in 4 hours and 20 minutes and 0.11 microgram/ml in 17 hours and 51 minutes. @entity8934 in umbilical cord serum was at detectable concentrations soon after administration and peaked to 23.5 micrograms/ml in 32 minutes. Although the concentrations in umbilical cord serum gradually decreased thereafter, they were higher than those in maternal serum at 3 hours and more after an injection and was 0.41 microgram/ml at 17 hours and 51 minutes. The @entity8934 in amniotic fluid became detectable a little later than @entity8934 in umbilical cord serum. The concentration of @entity8934 in amniotic fluid was below 1.00 microgram/ml at 30 minutes after administration. Concentrations then gradually increased to 21.3 micrograms/ml in 1 hour and 55 minutes and, even in 17 hours and 51 minutes, they were as high as 9.44 micrograms/ml. 2. In the clinical evaluation, @entity8934 was given to a total of 7 cases, i.e., 1 of @entity5870 , 2 of @entity7288 , 1 of @entity221 , and 3 of @entity2885 . The treatment showed satisfactory results, i.e. excellent result was obtained in 1 case, good in 5 and poor in 1 with an clinical efficacy rate of 85.7%. Microbiological examinations resulted in the isolation of 5 bacterial strains of 4 species and 1 fungal strain from 5 cases.(ABSTRACT TRUNCATED AT 250 WORDS)
